<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430612</url>
  </required_header>
  <id_info>
    <org_study_id>469</org_study_id>
    <secondary_id>U01HL080416</secondary_id>
    <secondary_id>R01 HL080416-01A1</secondary_id>
    <nct_id>NCT00430612</nct_id>
  </id_info>
  <brief_title>The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)</brief_title>
  <acronym>OBTAIN</acronym>
  <official_title>The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the PACE-MI (OBTAIN) registry is:

        -  Analyze beta-blocker dose response effect on outcome over two years

        -  Explore gender and minority differences in beta-blocker utilization and outcomes.

      In patients with Myocardial Infarction (MI) discharged from the hospital, beta-blocker dose
      will be predictive of survival.

      Exploratory analyses: Gender and racial effects—gender and race are, similarly, hypothesized
      to be predictive of post-MI survival.

      The existence of interactions between gender and beta-blocker effect as well as race and
      beta-blocker effect will also be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods

      All patients admitted to the coronary care areas with an acute myocardial infarction will be
      entered into the registry. At the time of discharge from the coronary care unit, clinical
      data will be entered. The registry will include approximately 6800 patients.

      As there is no intervention in the registry, the data to be collected are standard for
      quality assurance purposes and cannot practicably be carried out without waivers of consent
      and HIPAA authorization, there will be no consent specifically for registry patients at
      baseline. Systems have been implemented to ensure the registry data will remain confidential.
      Sites have received IRB approval of waiver of consent and HIPAA for the baseline registry
      data.

      Data to be collected will include demographic (including ethnic and race classifications
      according to NIH guidelines) data and information regarding the index myocardial infarction.
      Use of beta-blockers at discharge from the coronary care unit will be documented. In
      addition, beta-blocker use at hospital discharge will be noted. Data for the registry will be
      obtained from ER notes, admission notes, cardiac catheterization lab reports, medication
      lists, lab reports, and discharge summaries.

      Follow-Up

      Follow-up for registry patients will be conducted at year 1 and year 2 post-myocardial
      infarction. Data may be obtained via medical chart review, phone contact, and Social Security
      Death Index (SSDI). For follow-up information obtained via chart review or the SSDI, a
      detailed justification for waiver of HIPAA and consent requirements is attached to this
      protocol (see appendix 7). If phone contact is required with the patient, we are suggesting
      the following process:

        -  A letter should be sent out to the patient approximately one week prior to the contact
           in which the rationale for the study will be provided, as well as a delineation of the
           patient's right to participate or not to participate (by either providing or not
           providing the requested information).

        -  At telephone contact with the patient, the coordinator will document whether the patient
           consents to provide the information. If the patient consents, the coordinator will
           proceed to obtain the requested information.

        -  In the event that the participating institution's IRB requires a written, signed consent
           for this verbal contact, a written consent form template (see appendix 3) is provided.

      Data collected at follow-up interview will include vital status, beta-blocker use, other
      cardiac medications and any cardiovascular hospitalizations.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Total mortality at 2 years post myocardial infarction</measure>
    <time_frame>Measured at Years 1 and 2</time_frame>
    <description>Compare Kaplan Meier survival curves for the following 5 beta-blocker dose groups:
No beta-blockers - 12.5% (&gt;0 - 12.5%) 25% (&gt;12.5 - 25%) - 50% (&gt;25 - 50%) Full Dose (&gt;50%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total mortality - secondary analysis</measure>
    <time_frame>Measured at Year 1 and Year 2</time_frame>
    <description>Compare Kaplan-Meier survival curves for the following 2 beta-blocker dose groups:
Very Low Dose (&gt;0-25%) vs. High Dose (≥50%)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">6830</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Non-voluntary registry of consecutive patients diagnosed as having a MI at each study site</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        non-voluntary registry of consecutive patients diagnosed as having a MI at each study site
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

        1. Consecutive patients admitted with a myocardial infarction documented by both of the
        following:

          1. cardiac enzymes (CPK elevation &gt; two times or troponin elevation &gt; three times the
             upper limit of normal for the lab)

          2. Electrocardiographic changes and/or symptoms consistent with myocardial infarction
             (i.e. chest pain, shortness of breath)

        No Exclusion Criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Goldberger, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Little Rock Cardiology Clinic</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MemorialCare Heart and Vascular Institute - Long Beach Memorial Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Los Angeles VA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bridgeport Hospital</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cardiac and Vascular Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Regional Medical Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clarian Health/Methodist Research Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Nicollet</name>
      <address>
        <city>St. Louis Park</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Bethpage</city>
        <state>New York</state>
        <zip>11714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strong Memorial Hospital (University of Rochester School of Medicine)</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OhioHealth Research Institute</name>
      <address>
        <city>Colombus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Memorial Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amarillo Heart Clinic Research Institute, Inc.</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Heart PLLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Health Center</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Israel</country>
  </removed_countries>
  <reference>
    <citation>Wikstrand J, Hjalmarson A, Waagstein F, Fagerberg B, Goldstein S, Kjekshus J, Wedel H; MERIT-HF Study Group. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol. 2002 Aug 7;40(3):491-8.</citation>
    <PMID>12142116</PMID>
  </reference>
  <reference>
    <citation>Metra M, Torp-Pedersen C, Swedberg K, Cleland JG, Di Lenarda A, Komajda M, Remme WJ, Lutiger B, Scherhag A, Lukas MA, Charlesworth A, Poole-Wilson PA. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J. 2005 Nov;26(21):2259-68. Epub 2005 Jul 21.</citation>
    <PMID>16040619</PMID>
  </reference>
  <reference>
    <citation>Dobre D, van Veldhuisen DJ, Mordenti G, Vintila M, Haaijer-Ruskamp FM, Coats AJ, Poole-Wilson PA, Flather MD; SENIORS Investigators. Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. Am Heart J. 2007 Jul;154(1):109-15.</citation>
    <PMID>17584562</PMID>
  </reference>
  <reference>
    <citation>Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J. 2007 Dec;28(24):3012-9. Epub 2007 Nov 2. Review.</citation>
    <PMID>17981830</PMID>
  </reference>
  <reference>
    <citation>Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol. 1986 Apr 25;57(12):43F-49F.</citation>
    <PMID>2871745</PMID>
  </reference>
  <reference>
    <citation>Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie JX, Liu LS; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005 Nov 5;366(9497):1622-32.</citation>
    <PMID>16271643</PMID>
  </reference>
  <reference>
    <citation>POISE Study Group, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, Xavier D, Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Málaga G, Avezum A, Chan M, Montori VM, Jacka M, Choi P. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008 May 31;371(9627):1839-47. doi: 10.1016/S0140-6736(08)60601-7. Epub 2008 May 12.</citation>
    <PMID>18479744</PMID>
  </reference>
  <reference>
    <citation>Gottlieb S, Harpaz D, Shotan A, Boyko V, Leor J, Cohen M, Mandelzweig L, Mazouz B, Stern S, Behar S. Sex differences in management and outcome after acute myocardial infarction in the 1990s: A prospective observational community-based study. Israeli Thrombolytic Survey Group. Circulation. 2000 Nov 14;102(20):2484-90.</citation>
    <PMID>11076821</PMID>
  </reference>
  <reference>
    <citation>Wilkinson P, Laji K, Ranjadayalan K, Parsons L, Timmis AD. Acute myocardial infarction in women: survival analysis in first six months. BMJ. 1994 Sep 3;309(6954):566-9.</citation>
    <PMID>7916229</PMID>
  </reference>
  <reference>
    <citation>Mahon NG, McKenna CJ, Codd MB, O'Rorke C, McCann HA, Sugrue DD. Gender differences in the management and outcome of acute myocardial infarction in unselected patients in the thrombolytic era. Am J Cardiol. 2000 Apr 15;85(8):921-6.</citation>
    <PMID>10760327</PMID>
  </reference>
  <reference>
    <citation>Vaccarino V, Krumholz HM, Yarzebski J, Gore JM, Goldberg RJ. Sex differences in 2-year mortality after hospital discharge for myocardial infarction. Ann Intern Med. 2001 Feb 6;134(3):173-81.</citation>
    <PMID>11177329</PMID>
  </reference>
  <reference>
    <citation>A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982 Mar 26;247(12):1707-14.</citation>
    <PMID>7038157</PMID>
  </reference>
  <reference>
    <citation>Olsson G, Wikstrand J, Warnold I, Manger Cats V, McBoyle D, Herlitz J, Hjalmarson A, Sonneblick EH. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J. 1992 Jan;13(1):28-32.</citation>
    <PMID>1533587</PMID>
  </reference>
  <reference>
    <citation>Rochon PA, Anderson GM, Tu JV, Clark JP, Gurwitz JH, Szalai JP, Lau P. Use of beta-blocker therapy in older patients after acute myocardial infarction in Ontario. CMAJ. 1999 Nov 30;161(11):1403-8.</citation>
    <PMID>10906894</PMID>
  </reference>
  <reference>
    <citation>Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA. 1997 Jan 8;277(2):115-21.</citation>
    <PMID>8990335</PMID>
  </reference>
  <reference>
    <citation>Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998 Aug 20;339(8):489-97.</citation>
    <PMID>9709041</PMID>
  </reference>
  <reference>
    <citation>Haywood LJ. Coronary heart disease mortality/morbidity and risk in blacks. I: Clinical manifestations and diagnostic criteria: the experience with the Beta Blocker Heart Attack Trial. Am Heart J. 1984 Sep;108(3 Pt 2):787-93.</citation>
    <PMID>6148005</PMID>
  </reference>
  <reference>
    <citation>Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Málek I, Nyberg G, Rydén L, Swedberg K, Vedin A, Waagstein F, Waldenström A, Waldenström J, Wedel H, Wilhelmsen L, Wilhelmsson C. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. 1981 Oct 17;2(8251):823-7.</citation>
    <PMID>6116950</PMID>
  </reference>
  <reference>
    <citation>Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981 Apr 2;304(14):801-7.</citation>
    <PMID>7010157</PMID>
  </reference>
  <reference>
    <citation>Viskin S, Kitzis I, Lev E, Zak Z, Heller K, Villa Y, Zajarias A, Laniado S, Belhassen B. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol. 1995 May;25(6):1327-32.</citation>
    <PMID>7722129</PMID>
  </reference>
  <reference>
    <citation>The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999 Jan 2;353(9146):9-13.</citation>
    <PMID>10023943</PMID>
  </reference>
  <reference>
    <citation>Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001 May 5;357(9266):1385-90.</citation>
    <PMID>11356434</PMID>
  </reference>
  <reference>
    <citation>Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group. Eur Heart J. 1985 Mar;6(3):199-226.</citation>
    <PMID>2863148</PMID>
  </reference>
  <reference>
    <citation>American Heart Association. Heart disease and stroke statistics-2009 update. Dallas: American Heart Association; 2009.</citation>
  </reference>
  <reference>
    <citation>Dmitrienko A, Molenberghs G, Chuang-Stein C, Offen W. Analysis of clinical trials using SAS: A practical guide. Cary, NC: SAS Institute Inc.; 2005.</citation>
  </reference>
  <reference>
    <citation>Westfall PH. Multiple comparisons and multiple tests : using the SAS system. 1. print. ed. Cary NC: SAS Inst.; 1999.</citation>
  </reference>
  <reference>
    <citation>Tu JV, Willison DJ, Silver FL, Fang J, Richards JA, Laupacis A, Kapral MK; Investigators in the Registry of the Canadian Stroke Network. Impracticability of informed consent in the Registry of the Canadian Stroke Network. N Engl J Med. 2004 Apr 1;350(14):1414-21.</citation>
    <PMID>15070791</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2007</study_first_submitted>
  <study_first_submitted_qc>January 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2007</study_first_posted>
  <last_update_submitted>April 30, 2015</last_update_submitted>
  <last_update_submitted_qc>April 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Jeff Goldberger</investigator_full_name>
    <investigator_title>Principal Investigator, MD, MBA, Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Heart Attack</keyword>
  <keyword>Beta Blockers</keyword>
  <keyword>Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 4, 2015</submitted>
    <returned>January 15, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

